Uridine-rich small nuclear RNAs (U snRNAs) are involved in very important pre-mRNA splicing events in the nucleus of eukaryotic cells.^[@ref1]^ Among them, U1snRNA can recognize the 5′-splice site of pre-mRNA. At the first splicing step, U1snRNA directly binds to the splice site by hybridization between the 5′-terminal eight nucleotides of U1snRNA and the complementary sequence of pre-mRNA.^[@ref2]^

Splicing disorders are estimated to account for about 15% of disease-causing mutations in humans, and the majority of genetic mutations are point mutations within the sequences of splice sites.^[@ref3]^ A subset of these defects should result from mismatched base pairs between U1snRNA and mutant pre-mRNAs. It was reported in a recent study that mutant pre-mRNA splicing could be promoted by modified U1snRNAs that were prepared using the biological technique in the cell and could hybridize with the mutant pre-mRNA.^[@ref4]^ These results indicate that modified U1snRNA could be useful for splicing correction in gene therapy.

Additionally, a modified U1snRNA containing the sequence complementary to the 3′-terminal exon of the targeted gene can downregulate the targeted gene expression via U1 interference (U1i).^[@ref5]^ This downregulation results from inhibition of mRNA polyadenylation by the U1 snRNA-binding protein (U1--70K protein). However, U1 snRNA has never been chemically synthesized because U1 snRNA is very long (164 nt) and contains a complicated 5′-terminal 2,2,7-*N*-trimethylguanosine (m~3~^2,2,7^G) cap (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}a).^[@ref6]^ The m~3~^2,2,7^G cap can bind to the nuclear import adaptor snurportin 1 (SPN1) and plays an important role in transporting UsnRNAs between the cytoplasm and the nucleus. In this study, we carried out the chemical synthesis of U1snRNA and modified U1snRNAs containing the m~3~^2,2,7^G cap analogues for the first time, as shown in Figure [2](#fig2){ref-type="fig"}.

![Structure of U1snRNA.](ol-2013-01917r_0001){#fig1}

Figure [3](#fig3){ref-type="fig"} depicts the strategy for synthesizing U1snRNA with a fluorescent label at the 3′-terminus. First, we synthesized 5′-short RNA containing the m~3~^2,2,7^G cap by chemical reactions on polymer supports (Schemes [1](#sch1){ref-type="scheme"} and [2](#sch2){ref-type="scheme"}) and 3′-long RNA by biochemical methods using T7 RNA polymerase and a chemical reaction in solution phase (Scheme [3](#sch3){ref-type="scheme"}). We subsequently generated the complex formed between 5′-short RNA, 3′-long RNA, and the complementary splint DNA. After hybridization, the ligation reactions were carried out using T4 DNA ligase.^[@ref7]^

In the synthesis of 5′-short RNAs, we used the highly cross-linked polystyrene resin^[@ref8]^**1** that has a silyl-type linker,^[@ref9]^ which can be cleaved under neutral conditions, phosphoryl^[@ref10]^ and phosphityl reagents **2**--**4** (Figure [4](#fig4){ref-type="fig"}). The synthesis of 5′-short RNA **I** is shown in Scheme [1](#sch1){ref-type="scheme"}. After chain elongation of the RNA sequence using 2′-*O*-TBDMS RNA phosphoramidite units on the resin by using an RNA synthesizer, the treatment of resin **5** with 100 equiv of diphenyl phosphonate in pyridine was followed by hydrolysis mediated by a *H*-phosphonate compound. The compound was subsequently oxidized using (2*R*,8*S*)-(+)-(camphorsulfonyl)oxaziridine in the presence of *N,O*-bis(trimethylsilyl)acetamide (BSA). The 5′-terminal pyrophosphate bond was formed by the reaction of the protected oligonucleotide immobilized on the resin with compound **2** for 15 min, as shown in Scheme [1](#sch1){ref-type="scheme"}. After deprotection of the 2-cyanoethyl, sulfonylethyl, and *N*-acyl groups, the 5′-terminal capping reaction was performed by treating residue **6** with m~3~^2,2,7^G phosphorimidazolide unit **7**.^[@ref11]^ The 2′-TBDMS groups of the oligomer were subsequently deprotected, and the oligomer was released from the resin by treatment with 1 M tetrabutylammonium fluoride (TBAF) in the presence of 0.5 M AcOH for 24 h. Although the only 2′-TBDMS groups of pseudouridine residues could not be cleaved under the deprotection conditions using TBAF, the TBDMS groups were easily removed by treatment with a 20% acetic acid aqueous solution for 3 h.^[@ref12]^ The target 5′-short RNA **I** was isolated by anion-exchange HPLC in 2% yield and characterized by MALDI-TOF mass spectrometry. Additionally, the 5′-short RNA **II** having a pyrophosphate group was obtained as a byproduct in 3% isolated yield.

![Chemical structure of (a) m~3~^2,2,7^G cap, (b) pyrophosphate analogue, and (c) ethylene glycol analogue.](ol-2013-01917r_0002){#fig2}

![Strategy for U1snRNA synthesis.](ol-2013-01917r_0003){#fig3}

![Structure of resin **1**, phosphoryl and phosphityl reagents **2**--**4**.](ol-2013-01917r_0004){#fig4}

![Synthesis of 5′-Short RNA **I** Containing an m~3~^2,2,7^G Cap\
The sequence of oligonucleotide is A~m~U~m~ACΨΨAC.](ol-2013-01917r_0006){#sch1}

In the synthesis of 5′-short RNA **III** containing an m~3~^2,2,7^G cap analogue, the resin **8** was prepared by chain elongation using phosphityl reagents **3** and **4** on resin **1**. Resin **8** was treated with DBU and MeNH~2~ to obtain resin **9**. After capping using phosphorimidazolide unit **7**, the oligomer was deprotected and released from the resin in 12% isolated yield. The yield of 5′-short RNA **III** was much higher than that of RNA with an unmodified m~3~^2,2,7^G cap.

The 3′-long RNA was synthesized by RNA transcription using T7 RNA polymerase, as shown in Scheme [3](#sch3){ref-type="scheme"}. In this RNA transcription, we combined the desired RNA sequence and the hammerhead ribozyme sequence because efficient synthesis requires the RNA to have a purine-rich sequence at the 5′-terminus.^[@ref13]^ The 5′-sequence of hammerhead ribozyme was efficiently eliminated under the transcription conditions in the presence of Mg^2+^. After PAGE purification, we introduced a fluorescent label into the 3′-terminus of the RNA by treatment with NaIO~4~ and fluorescein-5-thiosemicarbazide in 65% isolated yield. For the final step, 5′-phosphorylation was carried out using T4 polynucleotide kinase.

![Synthesis of 5′-Short RNA **III** Containing an m~3~^2,2,7^G Cap Analogue\
The oligonucleotide sequence is A~m~U~m~ACΨΨAC.](ol-2013-01917r_0007){#sch2}

![Synthesis of 3′-Long RNA](ol-2013-01917r_0008){#sch3}

The 5′-short RNAs **I**--**III** were ligated with the 3′-long RNA by T4 DNA ligase to obtain the U1 snRNA **I** and its analogues (U1snRNA **2** with a pyrophosphate linkage and U1 snRNA **III** with an ethylene glycol linkage) with a fluorescent label in the presence of the complementary splint DNA. The target U1 snRNAs **I**--**III** were isolated by PAGE in 14, 28, and 30% yields, respectively, and characterized by MALDI-TOF mass spectrometry. These results are the first demonstration of the chemical synthesis of U1 snRNA and their analogues.

Moreover, we examined the binding affinities of U1 snRNA **I**--**III** to the nuclear import adaptor SPN 1, as shown in Figure [5](#fig5){ref-type="fig"}. The RNA without an m~3~^2,2,7^G cap could not specifically bind to SPN 1, though nonspecific binding was observed in 2 μM SPN1 due to electrostatic interaction between the phosphate groups of the RNA and lysine (or arginine) residues of SPN1 (Figure [5](#fig5){ref-type="fig"}a). On the other hand, U1 snRNA **I** with an m~3~^2,2,7^G cap could completely bind to SPN1 in 1 μM SPN1 in Figure [5](#fig5){ref-type="fig"}b. Figure [5](#fig5){ref-type="fig"}c and [5](#fig5){ref-type="fig"}d show the results of U1snRNAs with m~3~^2,2,7^G cap analogues. Interestingly, the binding affinity of the analogue with an ethylene glycol linkage was as high as that of U1 snRNA **I** with an m~3~^2,2,7^G cap, as shown in Figure [5](#fig5){ref-type="fig"}d, though the binding affinity of the U1 snRNA **II** with a pyrophosphate linkage was lower than that of U1 snRNA **I**. Ficner et al. previously reported that the m~3~^2,2,7^G interacts with another nucleobase and Trp276 of SNP1 in the crystal structure of the complex formed between SPN 1 and the m~3~^2,2,7^GpppG dimer.^[@cit6e]^ Therefore, the shortage of the atom length of the pyrophosphate linkage in U1 snRNA **II** might decrease the binding affinity to SPN 1. On the other hand, a longer linkage such as that afforded by ethylene glycol in U1 snRNA **III** might not affect the binding affinity to SPN 1.

![Electrophoretic mobility shift assay of the complexes formed between snurportin 1 (0--2 μM) and U1 snRNA **I**-**III** (50 nM) on a 16% nondenaturing polyacrylamide gel at pH 7.4. (a) U1snRNA without an m~3~^2,2,7^G cap, (b) unmodified U1 snRNA **I**, (c) modified U1 snRNA **II**, and (d) modified U1 snRNA **III** with an ethylene glycol linkage.](ol-2013-01917r_0005){#fig5}

In summary, we carried out a first chemical synthesis of U1snRNA and its analogues by a combination of solid-phase and enzymatic reactions. The synthesis of U1 snRNA **III** with an m~3~^2,2,7^G cap analogue was easier and more efficient than that of U1 snRNA I with an m~3~^2,2,7^G cap. Moreover, we found that the binding affinity of U1 snRNA **III** was as high as that of U1snRNA **I**. These results should be very useful for investigating splicing correction and U1i by an artificial U1 snRNA in gene therapy. Further studies on these issues are currently in progress.
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